Gabe Musso, Chief Scientific Officer will be leading a presentation on how BioSymetrics is redefining AI-based Drug Discovery during the MedTech Showcase at #JPM2020. Topics will include how phenotype prediction can increase certainty of compound effects in vivo, identify off-target effects, reduce toxicity and shorten the path to market.
Gabe Musso, Chief Science Offer will be speaking at the AI in Pharma summit in Boston on October 9th. His unique perspective on data management in drug discovery and clinical trials will try to wrestle with the timeless question on how to manage and process fragmented data.
BioSymetrics CSO Gabe Musso to Present on Artificial Intelligence and Machine Learning for Biomedical R&D Innovation at the 2019 BIO International Convention
PHILADELPHIA – (June 3, 2019) – Biomedical artificial intelligence (AI) company BioSymetrics will offer a presentation on the use of AI and machine learning for healthcare and biomedical R&D innovation at the 2019 BIO International Convention, which is being held June 3-6 at the Pennsylvania Convention Center in Philadelphia. The company’s Chief Scientific Office, Gabe Musso, will lead the presentation on Wednesday, June 5, at 11:15 am, in Theater 3. Read More
TORONTO – (May 21, 2019) – Biomedical artificial intelligence (AI) company BioSymetrics will be attending Collision 2019, which is being held May 20-23 at the Entercare Centre in Toronto. BioSymetrics is pioneering proprietary data science and machine learning software in order to best optimize medical discovery and life sciences productivity.
The company’s Chief Scientific Officer, Gabe Musso, will be available for meetings at Collision during the HealthConf track on Thursday, May 23, at BioSymetrics’ booth (Booth #B101) and can discuss how BioSymetrics’ inaugural product, the Augusta™ software platform, provides a holistic solution to some of the current industry challenges, including the utilization of good data without bias to feed machine learning models, as well as solving the ability to interrogate multiple models. BioSymetrics simplifies biomedical data science projects by reducing the time spent on data pre-processing, thus ultimately helping to build more effective predictive models that enable solutions to reach the market more quickly.
NOTE: Booth #B101 will be located in a different area on Thursday; please ask for directions at the information desk.
Media & Analyst Briefings
To schedule a briefing with BioSymetrics at Collision, please contact BioSymetrics’ PR team at 774-551-6679 or firstname.lastname@example.org.
For additional information, visit https://www.biosymetrics.com.
Korie Grill, Account Executive
Be sure to catch our presentation:
- Overcoming unwanted bias and time lost in data processing and management
- What is “Contingent AI?”
- Case Study: Autonomous Drug Screening